Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

Impact · against what's priced in

Positive post-hoc analysis for obe-cel in B-ALL patients with extramedullary disease suggests the drug is effective in a high-risk population typically associated with poor survival. This expands the potential utility and clinical value of the commercial-stage therapy.

AUTL+0.50

No priced-in read yet